References
- D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy and membranoproliferative glomerulonephritis: survey of the recent literature. Am. J. Kidney Dis. 1992; 20(4)315–323, [PUBMED], [INFOTRIEVE]
- Nolin L., Courteau M. Management of IgA nephropathy: evidence‐based recommendations. Kidney Int. 1999; 55(Suppl. 70)S56–S62, [CROSSREF]
- Lai K. N., Lai I. M., Ho C. P., Chan K. W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long‐term controlled trial. Clin. Nephrol. 1986; 26(4)174–180, [PUBMED], [INFOTRIEVE]
- Kobayashi Y., Hiki Y., Kokubo T., Horii A., Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10‐year follow‐up study. Nephron 1996; 72(2)237–242, [PUBMED], [INFOTRIEVE], [CSA]
- Pozzi C., Bolasco P. G., Fogazzi G. B., Andrulli S., Altieri P., Ponticelli C., Locatelli F. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 1999; 353: 883–887, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Locatelli F., Del Vecchio L., Pozzi C. The patient with IgA glomerulonephritis—what is the role of steroid treatment?. Nephrol. Dial. Transplant. 1999; 14(5)1057–1060, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Locatelli F., Pozzi C., Del Vecchio L., Andrulli S., Pani A., Fogazzi G., Altieri P., Ponticelli C. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomized multicenter trial. J. Nephrol. 1999; 12(5)308–311, [PUBMED], [INFOTRIEVE], [CSA]
- Ballardie F. W., Roberts I. S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J. Am. Soc. Nephrol. 2002; 13(1)142–148, [PUBMED], [INFOTRIEVE], [CSA]
- Goumenos D., Davlouros P., El Nahas A. M., Ahuja I`., Shortland J. R., Vlachojannis J. G., Brown C. B. Prednisolone and azathioprine in IgA nephropathy?. Nephron Clin. Pract. 2003; 93(2)C58–C68, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pettersson E. E., Rekola S., Berglund L., Sundqvist K. G., Angelin B., Diczfalusy U., Bjorkhem I., Bergstom J. Treatment of IgA nephropathy with omega‐3‐polyunsaturated fatty acids: a prospective double‐blind randomized study. Clin. Nephrol. 1994; 41(4)183–190, [PUBMED], [INFOTRIEVE], [CSA]
- Donadio J. V., Jr., Bergstralh E. J., Offord K. P., Spencer D. C., Holley K. E. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N. Engl. J. Med. 1994; 331(18)1194–1199, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dillon J. J. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J. Am. Soc. Nephrol. 1997; 8(11)1739–1744, [PUBMED], [INFOTRIEVE], [CSA]
- Donadio J. V., Grande J. R., Bergstralh E. J., Dart R. A., Larson T. S., Spencer D. C. The long‐term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999; 10: 1772–1777, [PUBMED], [INFOTRIEVE], [CSA]
- Cattran D. C., Greenwood C., Ritchie S. Long‐term benefits of angiotensin‐converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am. J. Kidney Dis. 1994; 23(2)247–254, [PUBMED], [INFOTRIEVE], [CSA]
- Ruggenenti P., Perna A., Gherardi G., Benini R., Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 2000; 35(6)116–1155